Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. on October 24, 2018. The registrant is a Delaware corporation focused on oncology, specifically the clinical development of Onvansertib and NPM1 mutation testing. Note: The request metadata lists "Cardiff Oncology, Inc.", but the filing text explicitly identifies the registrant as "Trovagene, Inc."
Key Financial Metrics
- Cash Runway: Management stated cash on hand is sufficient to meet needs until July 2019.
- Burn Rate: Approximately $4.5 million per quarter at the time of filing.
- Projected Burn Rate: Expected to increase to $5.0 million per quarter in 2020.
- Revenue, Profit, Debt, Liquidity: The filing text does not provide specific values for revenue, net income, total debt, or current liquidity ratios beyond the cash runway estimate.
Material Changes and Events
- Regulation FD Disclosure: The company held a conference call to review the Onvansertib clinical development program and provide a business update.
- Intellectual Property: The U.S. Patent and Trademark Office (USPTO) allowed claims for Patent Application 14/750331, affirming broad coverage for NPM1 mutation testing.
- Leadership: Thomas Adams is serving as Interim Chief Executive Officer.
Guidance, Outlook, and Risks
- Capital Needs: The company is not seeking to raise funds immediately but may look to raise an additional $10-$15 million in the future to fund cash needs through the first quarter of 2020.
- Operational Outlook: The company anticipates an increase in its quarterly cash burn rate from $4.5 million to $5.0 million in 2020.
- Risks: The primary risk highlighted is the need for future capital to sustain operations beyond the projected July 2019 runway.
Investor Verification Checklist
- Verify the exact cash balance as of the most recent 10-Q or 10-K to confirm the July 2019 runway estimate.
- Review the attached Investor Call Presentation (Exhibit 99.1) for detailed clinical data on Onvansertib.
- Confirm the status of the NPM1 mutation testing patent (Application 14/750331) via USPTO records.
- Monitor future filings for any announcements regarding the potential $10-$15 million capital raise.